Presbia (LENSF) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	12-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1591096
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		13,351,874

Consolidated_Balance_Sheets

Consolidated Balance Sheets(USD ($))	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash	$35,263	$138
Accounts receivable	44	25
Inventory	314	378
Prepaid expenses and other current assets	187	122
Total current assets	35,808	663
Property and equipment, net	792	747
Intangible asset	44	46
Other assets	57	886
Total assets	36,701	2,342
Current liabilities
Accounts payable	1,965	1,882
Due to related parties	161	12
Other current liabilities	550	700
Total current liabilities	2,676	2,594
Payable due to the Parent		417
Deferred rent	33	37
Total liabilities	2,709	3,048
Commitments and contingencies (note 10)
Shareholder's equity (deficit)
Preferred Shares $0.001 par value, 50,000,000 shares authorized; none issued
Ordinary shares	13
Additional paid-in capital	75,904	36,626
Accumulated deficit	-41,979	-37,386
Total shareholder's equity (deficit)	33,992	-706
Total liabilities and shareholders' equity (deficit)	$36,701	$2,342

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)(USD ($))	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
			Euro [Member]	Euro [Member]	United States of America, Dollars	United States of America, Dollars
Preferred shares, par value	$0.00	$0.00
Preferred shares, shares authorized	50,000,000	50,000,000
Preferred shares, shares issued	0	0
Ordinary shares, par value	$0.00	$0.00	$1	$1	$1.35	$1.35
Ordinary shares, shares authorized	350,000,000	350,000,000	40,000	40,000
Ordinary shares, shares issued	13,351,874	0	40,000	40,000
Ordinary shares, shares outstanding	13,351,874	0	40,000	40,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues	$73	$26
Cost of goods sold	47	6
Gross profit	26	20
Operating expenses:
Research and development	1,776	732
Sales and marketing	519	249
General and administrative	2,319	1,376
Total operating expenses	4,614	2,357
Operating loss	-4,588	-2,337
Interest expense		433
Loss before income tax provision	-4,588	-2,770
Income tax provision	5	2
Net loss	-4,593	-2,772
Other comprehensive loss	0	0
Total comprehensive loss	($4,593)	($2,772)
Net loss per share-basic and diluted	($0.39)	($0.30)
Shares used to compute basic and diluted net loss per share	11,762	9,167

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flow from operating activities:
Net loss	($4,593)	($2,772)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	36	32
Amortization	3	1
Inventory provisions	35
Share-based compensation (including allocation from Presbia Holdings)	852	109
Non-cash interest expense on funding from the Presbia Holdings	1	433
Non-cash operating expenses allocated from the Presbia Holdings		184
Changes in operating assets and liabilities:
Accounts receivable	-19
Inventory	28	-92
Prepaid expenses and other current assets	-65	-245
Other assets	-10
Accounts payable and other current liabilities	737	-175
Income taxes payable	4
Deferred rent	-4	-1
Due to related parties	149	-53
Net cash used in operating activities	-2,846	-2,579
Cash flow from investing activities:
Website development costs	0	0
Purchase of property and equipment	-47	-7
Net cash used in investing activities	-47	-7
Cash flow from financing activities:
Proceeds from issuance of ordinary shares upon initial public offering, net of underwriting costs	38,750
Deferred offering costs	-1,873	-913
Capitalization of Presbia PLC		54
Issuance of restricted shares	0	0
Funding from the Parent	1,141	3,068
Net cash provided by financing activities	38,018	2,209
Net increase in cash	35,125	-377
Cash balance at beginning of period	138	584
Cash balance at end of period	35,263	207
Supplemental disclosure of cash flow information:
Cash paid for income taxes	3
Supplemental disclosures of non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable	34
Deferred offering costs included in accounts payable and other current liabilities	521	1,123
Deferred offering costs included in Due to Presbia Holdings		650
Allocated operating expenses funded by the Presbia Holdings		184
Capitalization of amounts due to Presbia Holdings pursuant to the 2015 Debt Conversion	$1,559

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	-1	Basis of Presentation
	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a direct subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
	Presbia PLC, an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares for 40,000 Euros (approximately $54,000) for the purpose of consummating an initial public offering of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited.
	2015 Debt Conversion. On January 14, 2015, the Parent converted all the remaining indebtedness owed to the Parent by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. See Note 4 for additional discussion.
	2015 Capital Contribution. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of Presbia PLC. See Note 4 for additional discussion.
	Initial Public Offering. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The NASDAQ Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares in the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million, less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $1.9 million, resulting in net proceeds of approximately $36.9 million.
	Basis of Presentation. The accompanying unaudited consolidated financial statements as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 have been prepared in accordance with the requirements of Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Amounts related to disclosures of December 31, 2014 balances within these interim consolidated financial statements were derived from the aforementioned Form 10-K. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.
	References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
	Liquidity
	The Company has incurred significant operating losses since inception and had relied on funding from the Parent to fund operations prior to its IPO on February 3, 2015. At March 31, 2015, the Company has an accumulated deficit of $42.0 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of March 31, 2015 will be sufficient to fund the Company’s operations for the next 12 months.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	-2	Summary of Significant Accounting Policies
	Revenue Recognition
	The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. As of March 31, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers.
	Clinical Trials
	During 2014, the Company received approval from the FDA to commence a staged-enrollment pivotal FDA clinical trial of its microlens involving the implantation of presbyopic patients. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. In February 2015, the Company received approval from the FDA to commence second stage enrollment in this trial. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
	Share-Based Compensation
	The following table shows total share-based compensation expense included in the consolidated statements of operations and comprehensive income for the three months ended March 31, 2015 and 2014:
			THREE MONTHS ENDED
			MARCH 31,
			2015		2014
	Research and development		$	26	$	83
	General and administrative			796		21
	Sales and marketing			30		5
	Total		$	852	$	109
	Deferred Offering Costs
	During the three months ended March 31, 2015, the Company incurred approximately $1.0 million related to its IPO which was completed on February 3, 2015. Upon completion of the IPO, the Company netted approximately $1.9 million in offering costs against the gross proceeds in shareholders’ deficit.
	Fair Value of Financial Instruments
	The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, which has no fixed maturity or expiration date, do not have readily determinable fair values.
	Recent Accounting Standards
	In January 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-01 which simplifies income statement presentation by eliminating the need to determine whether to classify an item as an extraordinary item. This ASU applies to all entities and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, but adoption must occur at the beginning of a fiscal year. An entity can elect to apply the guidance prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Composition of Certain Financial Statement Captions	-3	Composition of Certain Financial Statement Captions
	Inventory is summarized as follows:
			March 31,			December 31,
			2015			2014
	Lenses		$	303		$	371
	Accessories			11			7
	Total		$	314		$	378
	Property and equipment is summarized as follows:
			March 31,			December 31,
			2015			2014
	Office equipment and computers		$	51		$	51
	Leasehold improvements			134			132
	Production equipment and facilities			711			682
	Software			23			7
	Construction in process			33			0
	Furniture and vehicles			156			155
				1,108			1,027
	Less: accumulated depreciation			(316	)		(280	)
	Property & Equipment, net		$	792		$	747
	Other assets are summarized as follows:
			March 31,			December 31,
			2015			2014
	Prepaid rent and other		$	57		$	47
	Deferred costs related to IPO			—			839
	Total		$	57		$	886
	Other current liabilities are summarized as follows:
			March 31,			December 31,
			2015			2014
	Costs related to the IPO		$	—		$	327
	Accrued professional fees			224			20
	Accrued payroll and vacation			40			114
	Other accrued liabilities			286			230
	Total		$	550		$	691

Shareholders_Deficit

Shareholders' Deficit	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Shareholders' Deficit	-4	Shareholders’ Deficit
	Euro Ordinary Shares
	As of March 31, 2015, the share capital of Presbia PLC was €40,000, consisting of 40,000 ordinary shares of one Euro each (the “Euro Ordinary Shares”). The Euro Ordinary Shares were issued and paid-in on February 6, 2014 in connection with the formation of Presbia PLC. On January 14, 2015, Presbia PLC amended its memorandum and articles of association, resulting in the re-designation of the 40,000 Euro Ordinary Shares as deferred ordinary shares. See discussion following under the caption “Common Ordinary Shares and Deferred Ordinary Shares” for a description of the amended rights and preferences of the deferred ordinary shares.
	Common Ordinary Shares and Deferred Ordinary Shares
	As of January 14, 2015, the share capital of Presbia PLC was $400,000 and €40,000, divided into 350,000,000 ordinary shares of $0.001 each (the “Ordinary Shares”), 9,166,667 of which are outstanding and were issued in connection with the 2015 Capital Contribution, 50,000,000 preferred shares of $0.001 (the “Preferred Shares”) each, all of which are authorized but unissued, and 40,000 deferred ordinary shares of €1.00 each (the “Deferred Ordinary Shares”), all of which are issued and outstanding. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of comparable basic and diluted net loss per share. On February 3, 2015, the Company completed its IPO and issued 4,166,667 ordinary shares at a price to the public of $10.00 per share.
	The rights and restrictions attaching to the Ordinary Shares are as follows: the right to attend and speak at any general meeting of the Company and to exercise one vote per Ordinary Share held at any general meeting of the Company; the right to participate pro rata in all dividends declared by the Company; and the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company.
	The rights and restrictions attaching to the Deferred Ordinary Shares are as follows:
	Income: The holder of a Deferred Ordinary Share shall not be entitled to receive any dividend or distribution declared, made or paid or any return of capital (save as provided below) and a Deferred Ordinary Share shall not entitle its holder to any further or other right of participation in the assets of the Company;
	Capital: On a winding up of, or other return of capital (other than on a redemption of any class of shares in the capital of the Company) by the Company, the holders of Deferred Ordinary Shares shall be entitled to participate in such return of capital or winding up of the Company, such entitlement to be limited to the repayment of the amount paid up or credited as paid up on such Deferred Ordinary Shares and shall be paid only after the holders of Ordinary Shares shall have received payment in respect of such amount as is paid up or credited as paid up on those Ordinary Shares held by them at that time, plus the payment in cash of $5,000,000 on each such Ordinary Share.
	Acquisition of Deferred Ordinary Shares: The Company as agent for the holders of Deferred Ordinary Shares shall have the irrevocable authority to authorize and instruct the Company’s secretary (or any other person appointed for the purpose by the Company’s board of directors) to acquire, or to accept the surrender of, the Deferred Ordinary Shares for no consideration and to execute on behalf of such holders such documents as are necessary in connection with such acquisition or surrender, and pending such acquisition or surrender to retain the certificates, to the extent issued, for such Deferred Ordinary Shares.
	Voting: The holders of Deferred Ordinary Shares shall not be entitled to receive notice of, nor attend, speak or vote at, any general meeting.
	The rights attaching to the Preferred Shares will be determined by the Company’s board of directors. The directors are authorized to issue all or any of the authorized but unissued Preferred Shares from time to time in one or more classes or series, and to fix for each such class or series such voting power, full or limited, or no voting power, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board providing for the issuance of such class or series, including, without limitation, the authority to provide that any such class or series may be: redeemable at the option of the Company, or the holders, or both, with the manner of the redemption to be set by the Company’s board of directors, and redeemable at such time or times, including upon a fixed date, and at such price or prices, as shall be determined by the Board; entitled to receive dividends (which may be cumulative or non-cumulative) at such rates, on such conditions and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or classes of shares or any other series all as shall be determined by the Board; entitled to such rights upon the dissolution of, or upon any distribution of the assets of, the Company, as shall be determined by the Board; or convertible into, or exchangeable for, shares of any other class or classes of shares, or of any other series of the same or any other class or classes of shares, of the Company, at such price or prices or at such rates of exchange and with such adjustments as the Company’s board of directors determines.
	Additional Paid-in Capital
	On January 14, 2015, the Parent entered into a Debt Conversion Agreement pursuant to which all outstanding amounts owed to the Parent under the Interest Rate Agreement governing such debt at that time were contributed to paid-in capital of certain of the Parent’s subsidiaries.
	Additional paid-in capital was $75.9 million as of March 31, 2015, compared to $36.6 million as of December 31, 2014. The change consists of a contribution of approximately $1.6 million pursuant to the Debt Conversion Agreement, share-based compensation of $0.8 million and net proceeds of $36.9 million from the Company’s IPO.

Loss_per_Share

Loss per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Loss per Share	-5	Loss per Share
	Unvested share-based payment awards that contain non-forfeitable rights to dividends are participating securities that should be included in computing loss per share using the two-class method. The Company’s nonvested restricted shares qualify as participating securities. Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded.
	Basic and diluted loss per share were calculated as follows:
			THREE MONTHS ENDED MARCH 31,
			2015			2014
	Net loss		$	(4,593	)	$	(2,772	)
	Net income allocated to participating securities			—			—
	Net loss allocated to common shareholders		$	(4,593	)	$	(2,772	)
	Weighted average shares outstanding - basic and diluted			11,762			9,167
	Basic and diluted net loss per share		$	(0.39	)	$	(0.30	)
	The aggregate 9,166,667 ordinary shares of the Company as discussed in Note 4 have been reflected as issued and outstanding as March 31, 2014 for purposes of computation of basic and diluted net loss per share. Antidilutive securities, which consist of options and restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of approximately 653,951 and 0 weighted average shares for the three months ended March 31, 2015 and 2014, respectively.

Share_Based_Awards

Share Based Awards	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Awards	-6	Share Based Awards
	Equity Issued by Parent
	Prior to January 14, 2015 and the Company’s IPO, the Parent granted options to purchase its ordinary shares and granted awards of restricted ordinary shares, to both employees and non-employees of the Company and share-based compensation related to such awards is recognized as expense in the accompanying consolidated financial statements. Information regarding prior period awards is available in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
	Options
	No options were granted by the Parent during the three months ended March 31, 2015. As of March 31, 2015, there were options outstanding to purchase 4,741,250 of the Parent’s ordinary shares.
	The following table sets forth the Parent’s option activity for the three months ended March 31, 2015:
	PARENT		NUMBER OF			WEIGHTED		AGGREGATE
			PARENT’S			AVERAGE		INTRINSIC
			SHARES			EXERCISE		VALUE
						PRICE PER
						SHARE
	Balance, December 31, 2014			4,835,000		$	0.11
	Granted			—		$	—
	Exercised			(75,000	)	$	0.08	$	12
	Forfeited/cancelled			(18,750	)	$	—
	Balance, March 31, 2015			4,741,250		$	0.11	$	1,070
	Vested and expected to vest, March 31, 2015			4,721,276		$	0.11	$	1,068
	Exercisable, March 31, 2015			4,176,250		$	0.09	$	1,013
	Restricted Shares
	No restricted shares were granted by the Parent during the three months ended March 31, 2015. As of March 31, 2015, there were 1,500,000 restricted shares of the Parent outstanding with a weighted average grant date fair value of $0.30 per share. The Company recorded compensation expense related to restricted shares of approximately $7,400 for the three months ended March 31, 2015.
	Unrecognized Share-based Compensation
	As of March 31, 2015, there was $89,400 and $7,400 of unrecognized compensation expense related to employee and non-employee options of the Parent, respectively, which is expected to be recognized by the Company over the weighted average vesting period of 3.3 years. Unrecognized compensation expense related to restricted shares was $107,000 as of March 31, 2015 and is expected to be recognized over the weighted average vesting period of 3.6 years.
	Equity Issued by Presbia PLC
	Presbia Incentive Plan
	On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 1,800,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the 2005 Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company.
	Options
	On January 28, 2015, the Company’s board of directors approved grants to the following officers and directors, effective upon the execution of the underwriting agreement relating to the Company’s IPO: to Ralph Thurman, options to purchase 250,000 ordinary shares; to Zohar Loshitzer, options to purchase 100,000 ordinary shares; to Vladimir Feingold, options to purchase 100,000 ordinary shares; to Todd Cooper, options to purchase 450,000 ordinary shares; to Richard Ressler, options to purchase 10,000 ordinary shares; and to Mark Blumenkranz, options to purchase 10,000 ordinary shares. All such options were granted pursuant to the Presbia Incentive Plan at an exercise price of $10.00 per share and equal to the price at which the Company’s ordinary shares were offered to the public in its IPO. The options granted to Messrs. Loshitzer, Feingold and Cooper will vest in five equal annual installments commencing on January 28, 2016. The options granted to Messrs. Thurman, Ressler and Blumenkranz vested with respect to one-third of the underlying ordinary shares on the grant date and will vest with respect to one-third of the underlying ordinary shares on each of the next two anniversaries of that date. All options awarded will expire 10 years from the date of grant.
	On March 16, 2015, the Company’s board of directors approved option awards of 10,000 options each, respectively, to Richard Fogarty, Chief Accounting Officer, and to Jake Vander Zanden, Chief Commercial Officer, and an aggregate 82,500 options were granted to other employees and non-employees vesting in five equal, annual installments commencing one year following the date of grant, at an exercise price of $8.63 per share. All options awarded will expire 10 years from the date of grant. As of March 31, 2015, all 102,500 options were outstanding.
	The following table sets forth the Company’s option activity for the three months ended March 31, 2015:
	PRESBIA PLC		NUMBER OF			WEIGHTED		AGGREGATE
			SHARES			AVERAGE		INTRINSIC
						EXERCISE		VALUE
						PRICE PER
						SHARE
	Balance, December 31, 2014			—		$	—
	Granted			1,022,500		$	9.86
	Balance, March 31, 2015			1,022,500		$	9.86	$	—
	Vested and expected to vest, March 31, 2015			910,184		$	9.87	$	—
	Exercisable, March 31, 2015			90,000		$	10	$	—
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions. The Company estimated expected life utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of the “plain-vanilla” options. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.
			Three Months Ended
			March 31, 2015
	Expected life			5.5 - 6.5 years
	Expected volatility			76.8% - 84.6%
	Expected dividends			—
	Risk-free rate			1.3% - 1.8%
	The weighted-average grant date fair value of options granted during the three months ended March 31, 2015 was $6.99 per share.
	Restricted Shares
	On March 16, 2015, the Company’s board of directors approved grants of 9,270 restricted ordinary shares of the Company each to Robert J. Cresci and to Mark Blumenkranz, both of whom are board members. The aggregate 18,540 shares vest in five equal, annual installments commencing one year after the date of grant. The weighted-average grant date fair value for the restricted shares was estimated using the market price of the ordinary shares on the date of grant ($8.63 per share on March 16, 2015).
	As of March 31, 2015, there were 18,540 restricted shares of the Company outstanding with a weighted average grant date fair value of $8.63 per share. The Company recorded compensation expense related to restricted shares of approximately $1,300 for the three months ended March 31, 2015.
	Unrecognized Share-based Compensation
	As of March 31, 2015, there was $5.4 million and $62,000 of unrecognized compensation expense related to employee and non-employee options of the Company, respectively, which is expected to be recognized by the Company over the weighted average vesting period of 4.3 years. Unrecognized compensation expense related to restricted shares was $159,000 as of March 31, 2015 and is expected to be recognized over the weighted average vesting period of 5.0 years.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	-7	Related Party Transactions
	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets:
			March 31,		December 31,
			2015		2014
	Payable to related parties – current
	Management services provided by related parties		$	161	$	12
	Total		$	161	$	12
	Payable to related parties – noncurrent
	Principle amounts due to the Parent		$	—	$	417
	Total		$	—	$	417

Concentration_of_Credit_Risk

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	-8	Concentration of Credit Risk
	The Company had cash of $35.3 million and $138,000 as of March 31, 2015 and December 31, 2014, respectively, which consists of checking account deposits.

Operating_Segments_and_Geograp

Operating Segments and Geographic Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Operating Segments and Geographic Information	-9	Operating Segments and Geographic Information
	The Company has one reportable segment that is evaluated regularly by its chief decision making group (consisting of the Chief Executive Officer and Chief Accounting Officer) in deciding how to allocate resources and in assessing performance.
	The following tables set forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area:
			Three Months Ended March 31,
	REVENUES		2015		2014
	Ireland		$	34	$	22
	Korea			36		—
	Japan			—		4
	Canada			3		—
	Total		$	73	$	26
	LONG LIVED ASSETS		March 31,		December 31,
			2015		2014
	U.S.		$	762	$	716
	Foreign			30		31
	Total		$	792	$	747

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	-10	Commitments and Contingencies
	From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	-11	Subsequent Events
	In May 2015, the board of directors and shareholders of the Parent approved a plan to voluntarily liquidate the Parent and distribute, in August 2015, to its ordinary shareholders of record as of June 15, 2015, the remaining assets of the company, consisting primarily of 9,666,667 shares of Presbia PLC. The liquidation plan provides for (i) the unvested portions of the 4,741,250 outstanding options and 1,500,000 restricted shares as of March 31, 2015 to vest immediately, and (ii) the expiration date of the outstanding options to be set as June 15, 2015.
	On May 7, 2015, the Company’s board of directors approved option grants covering an aggregate of 12,500 shares to be granted under the Presbia Incentive Plan to three employees at an exercise price of $8.82 per share and vesting in five equal, annual installments commencing one year following the date of grant. Such options expire 10 years from the grant date.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a direct subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
	Presbia PLC, an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares for 40,000 Euros (approximately $54,000) for the purpose of consummating an initial public offering of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited.
Basis of Presentation	Basis of Presentation. The accompanying unaudited consolidated financial statements as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 have been prepared in accordance with the requirements of Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Amounts related to disclosures of December 31, 2014 balances within these interim consolidated financial statements were derived from the aforementioned Form 10-K. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.
	References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
Liquidity	Liquidity
	The Company has incurred significant operating losses since inception and had relied on funding from the Parent to fund operations prior to its IPO on February 3, 2015. At March 31, 2015, the Company has an accumulated deficit of $42.0 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of March 31, 2015 will be sufficient to fund the Company’s operations for the next 12 months.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. As of March 31, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers.
Clinical Trials	Clinical Trials
	During 2014, the Company received approval from the FDA to commence a staged-enrollment pivotal FDA clinical trial of its microlens involving the implantation of presbyopic patients. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. In February 2015, the Company received approval from the FDA to commence second stage enrollment in this trial. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Deferred Offering Costs	Deferred Offering Costs
	During the three months ended March 31, 2015, the Company incurred approximately $1.0 million related to its IPO which was completed on February 3, 2015. Upon completion of the IPO, the Company netted approximately $1.9 million in offering costs against the gross proceeds in shareholders’ deficit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Recent Accounting Standards	Recent Accounting Standards
	In January 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-01 which simplifies income statement presentation by eliminating the need to determine whether to classify an item as an extraordinary item. This ASU applies to all entities and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, but adoption must occur at the beginning of a fiscal year. An entity can elect to apply the guidance prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Income	The following table shows total share-based compensation expense included in the consolidated statements of operations and comprehensive income for the three months ended March 31, 2015 and 2014:
		THREE MONTHS ENDED
		MARCH 31,
		2015		2014
	Research and development	$	26	$	83
	General and administrative		796		21
	Sales and marketing		30		5
	Total	$	852	$	109

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Inventory	Inventory is summarized as follows:
		March 31,			December 31,
		2015			2014
	Lenses	$	303		$	371
	Accessories		11			7
	Total	$	314		$	378
Summary of Property and Equipment	Property and equipment is summarized as follows:
		March 31,			December 31,
		2015			2014
	Office equipment and computers	$	51		$	51
	Leasehold improvements		134			132
	Production equipment and facilities		711			682
	Software		23			7
	Construction in process		33			0
	Furniture and vehicles		156			155
			1,108			1,027
	Less: accumulated depreciation		(316	)		(280	)
	Property & Equipment, net	$	792		$	747
Summary of Other Assets	Other assets are summarized as follows:
		March 31,			December 31,
		2015			2014
	Prepaid rent and other	$	57		$	47
	Deferred costs related to IPO		—			839
	Total	$	57		$	886
Summary of Other Current Liabilities	Other current liabilities are summarized as follows:
		March 31,			December 31,
		2015			2014
	Costs related to the IPO	$	—		$	327
	Accrued professional fees		224			20
	Accrued payroll and vacation		40			114
	Other accrued liabilities		286			230
	Total	$	550		$	691

Loss_per_Share_Tables

Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted loss per share were calculated as follows:
		THREE MONTHS ENDED MARCH 31,
		2015			2014
	Net loss	$	(4,593	)	$	(2,772	)
	Net income allocated to participating securities		—			—
	Net loss allocated to common shareholders	$	(4,593	)	$	(2,772	)
	Weighted average shares outstanding - basic and diluted		11,762			9,167
	Basic and diluted net loss per share	$	(0.39	)	$	(0.30	)

Share_Based_Awards_Tables

Share Based Awards (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Option Activity	The following table sets forth the Company’s option activity for the three months ended March 31, 2015:
	PRESBIA PLC	NUMBER OF			WEIGHTED		AGGREGATE
		SHARES			AVERAGE		INTRINSIC
					EXERCISE		VALUE
					PRICE PER
					SHARE
	Balance, December 31, 2014		—		$	—
	Granted		1,022,500		$	9.86
	Balance, March 31, 2015		1,022,500		$	9.86	$	—
	Vested and expected to vest, March 31, 2015		910,184		$	9.87	$	—
	Exercisable, March 31, 2015		90,000		$	10	$	—
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions. The Company estimated expected life utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of the “plain-vanilla” options. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.
		Three Months Ended
		March 31, 2015
	Expected life		5.5 - 6.5 years
	Expected volatility		76.8% - 84.6%
	Expected dividends		—
	Risk-free rate		1.3% - 1.8%
Presbia Holdings [Member]
Schedule of Option Activity	The following table sets forth the Parent’s option activity for the three months ended March 31, 2015:
	PARENT	NUMBER OF			WEIGHTED		AGGREGATE
		PARENT’S			AVERAGE		INTRINSIC
		SHARES			EXERCISE		VALUE
					PRICE PER
					SHARE
	Balance, December 31, 2014		4,835,000		$	0.11
	Granted		—		$	—
	Exercised		(75,000	)	$	0.08	$	12
	Forfeited/cancelled		(18,750	)	$	—
	Balance, March 31, 2015		4,741,250		$	0.11	$	1,070
	Vested and expected to vest, March 31, 2015		4,721,276		$	0.11	$	1,068
	Exercisable, March 31, 2015		4,176,250		$	0.09	$	1,013

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets:
		March 31,		December 31,
		2015		2014
	Payable to related parties – current
	Management services provided by related parties	$	161	$	12
	Total	$	161	$	12
	Payable to related parties – noncurrent
	Principle amounts due to the Parent	$	—	$	417
	Total	$	—	$	417

Operating_Segments_and_Geograp1

Operating Segments and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following tables set forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area:
		Three Months Ended March 31,
	REVENUES	2015		2014
	Ireland	$	34	$	22
	Korea		36		—
	Japan		—		4
	Canada		3		—
	Total	$	73	$	26
	LONG LIVED ASSETS	March 31,		December 31,
		2015		2014
	U.S.	$	762	$	716
	Foreign		30		31
	Total	$	792	$	747

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jan. 14, 2015

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Jan. 14, 2015

Mar. 31, 2014

Feb. 06, 2014

Feb. 06, 2014

Feb. 06, 2014

Feb. 03, 2015

Mar. 31, 2015

Feb. 03, 2015

Jan. 14, 2015

Feb. 03, 2015

USD ($)

USD ($)

USD ($)

USD ($)

2015 Capital Contribution [Member]

2015 Capital Contribution [Member]

Presbia Holdings [Member]

Presbia Holdings [Member]

Presbia Holdings [Member]

IPO [Member]

IPO [Member]

IPO [Member]

IPO [Member]

IPO [Member]

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

2015 Capital Contribution [Member]

Presbia Holdings [Member]

Basis Of Presentation [Line Items]

Date of incorporation

6-Feb-14

Number of ordinary shares, shares issued

9,166,667

9,166,667

40,000

40,000

4,166,667

9,166,667

500,000

Number of ordinary shares, value

$54,000

€ 40,000

Percentage of ownership interests

100.00%

Capitalization of amounts due to Presbia Holdings pursuant to the 2015 Debt Conversion

1,600,000

1,559,000

Ordinary shares, price per share

$10

Gross proceeds from issuance of stock

38,750,000

41,700,000

Underwriting discounts and commission costs

2,900,000

Other issuance costs

1,873,000

913,000

1,900,000

1,900,000

Net proceeds from issuance of stock

36,900,000

36,900,000

Accumulated deficit

($41,979,000)

($37,386,000)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Income (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$852,000	$109,000
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	26,000	83,000
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	796,000	21,000
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$30,000	$5,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 03, 2015
Subsidiary, Sale of Stock [Line Items]
Payment of offering costs	$1,873,000	$913,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs	1,000,000
Payment of offering costs	$1,900,000		$1,900,000

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions - Summary of Inventory (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]
Total	$314	$378
Lenses [Member]
Inventory [Line Items]
Total	303	371
Accessories [Member]
Inventory [Line Items]
Total	$11	$7

Composition_of_Certain_Financi3

Composition of Certain Financial Statement Captions - Summary of Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$1,108	$1,027
Less accumulated depreciation	-316	-280
Property & Equipment, net	792	747
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51	51
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	134	132
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	711	682
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	23	7
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	33	0
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$156	$155

Composition_of_Certain_Financi4

Composition of Certain Financial Statement Captions - Summary of Other Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Assets Noncurrent Disclosure [Line Items]
Prepaid rent and other	$57	$47
Total	57	886
IPO [Member]
Other Assets Noncurrent Disclosure [Line Items]
Deferred costs related to IPO		$839

Composition_of_Certain_Financi5

Composition of Certain Financial Statement Captions - Summary of Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Liabilities, Current [Abstract]
Costs related to the IPO		$327
Accrued professional fees	224	20
Accrued payroll and vacation	40	114
Other accrued liabilities	286	230
Total	$550	$700

Shareholders_Deficit_Additiona

Shareholders' Deficit - Additional Information (Detail)	3 Months Ended					0 Months Ended	3 Months Ended		0 Months Ended	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 14, 2015	Jan. 14, 2015	Dec. 31, 2014	Feb. 03, 2015	Mar. 31, 2015	Feb. 03, 2015	Jan. 14, 2015	Mar. 31, 2014	Jan. 14, 2015	Jan. 14, 2015	Mar. 31, 2015	Mar. 31, 2015	Jan. 14, 2015	Dec. 31, 2014
	USD ($)		USD ($)	EUR (€)	USD ($)	IPO [Member]	IPO [Member]	IPO [Member]	2015 Capital Contribution [Member]	2015 Capital Contribution [Member]	2015 Capital Contribution [Member]	Ordinary Shares [Member]	Euro [Member]	Euro [Member]	Euro [Member]	Euro [Member]
						USD ($)	USD ($)	USD ($)			IPO [Member]	USD ($)	USD ($)	EUR (€)		USD ($)
Class of Stock [Line Items]
Share capital			$400,000	€ 40,000									$40,000
Ordinary shares	13,000												54,000	40,000		54,000
Deferred ordinary shares															40,000
Ordinary shares, par value	$0.00			€ 1	$0.00							$0.00	$1			$1
Shares authorized	350,000,000		350,000,000	350,000,000	350,000,000								40,000	40,000		40,000
Number of ordinary shares, shares issued						4,166,667			9,166,667	9,166,667	9,166,667
Weighted average shares outstanding - basic and diluted	11,762,000	9,167,000							9,166,667	9,166,667
Preferred shares, authorized	50,000,000		50,000,000	50,000,000	50,000,000
Preferred shares, par value	$0.00		$0.00		$0.00
Ordinary shares, price per share								$10
Payment for ordinary share	5,000,000
Additional paid-in capital	75,904,000				36,626,000
Capital contribution related to debt conversion	1,600,000
Capital contribution related to share-based compensation	800,000
Net proceeds from issuance of stock						$36,900,000	$36,900,000

Loss_per_Share_Schedule_of_Cal

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($4,593)	($2,772)
Net income allocated to participating securities	0	0
Net loss allocated to common shareholders	($4,593)	($2,772)
Weighted average shares outstanding - basic and diluted	11,762	9,167
Basic and diluted net loss per share	($0.39)	($0.30)

Loss_per_Share_Additional_Info

Loss per Share - Additional Information (Detail)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 14, 2015
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average shares outstanding - basic and diluted	11,762,000	9,167,000
Antidilutive securities, not included in diluted net loss per calculation	653,951	0
2015 Capital Contribution [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Ordinary shares, shares issued		9,166,667	9,166,667
Weighted average shares outstanding - basic and diluted		9,166,667	9,166,667

Share_Based_Awards_Additional_

Share Based Awards - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 16, 2015	Jan. 28, 2015	Jan. 14, 2015	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	1,022,500
Options outstanding	1,022,500					1,022,500
Compensation expense	$852,000	$109,000
Weighted average exercise price	$9.86
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0
Options outstanding	4,741,250					4,741,250	4,835,000
Unrecognized compensation expense related to employee	89,400,000					89,400,000
Unrecognized compensation expense related to restricted shares	107,000,000					107,000,000
Presbia Holdings [Member] | Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted	0
Restricted shares outstanding	1,500,000					1,500,000
Weighted average grant date fair value related to restricted shares outstanding	$0.30					$0.30
Compensation expense	7,400
Weighted average vesting period	3 years 7 months 6 days
Presbia Holdings [Member] | Non-employee stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to non-employee	7,400,000
Weighted average vesting period	3 years 3 months 18 days
Presbia Holdings [Member] | Employee stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average vesting period	3 years 3 months 18 days
Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	102,500					102,500
Unrecognized compensation expense related to employee	5,400,000					5,400,000
Unrecognized compensation expense related to restricted shares	159,000,000					159,000,000
Weighted average exercise price			$8.63	$10
Weighted average grant date fair value	$6.99
Restricted shares granted			9,270
Subsidiaries [Member] | Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average vesting period					5 years
Ordinary shares authorized for issuance					1,800,000
Award expiration period					10 years
Award expiration date	14-Jan-25
Generally vesting percentage for annual					20.00%
Subsidiaries [Member] | Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares outstanding	18,540					18,540
Compensation expense	1,300,000
Weighted average vesting period	5 years
Weighted average grant date fair value			$8.63			$8.63
Subsidiaries [Member] | Non-employee stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted			82,500
Unrecognized compensation expense related to non-employee	$62,000,000
Weighted average vesting period	4 years 3 months 18 days
Subsidiaries [Member] | Employee stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted			82,500
Weighted average vesting period	4 years 3 months 18 days
Award expiration period				10 years
Vesting description	The options granted to Messrs. Loshitzer, Feingold and Cooper will vest in five equal annual installments commencing on January 28, 2016. The options granted to Messrs. Thurman, Ressler and Blumenkranz vested with respect to one-third of the underlying ordinary shares on the grant date and will vest with respect to one-third of the underlying ordinary shares on each of the next two anniversaries of that date. All options awarded will expire 10 years from the date of grant.
Subsidiaries [Member] | Employee stock option [Member] | Richard Fogarty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards			10,000
Subsidiaries [Member] | Employee stock option [Member] | Jake Vander Zanden [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards			10,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Ralph Thurman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				250,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Zohar Loshitzer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				100,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Vladimir Feingold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				100,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Todd Cooper [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				450,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Richard Ressler [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				10,000
Subsidiaries [Member] | Employee stock option [Member] | IPO [Member] | Mark Blumenkranz [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards				10,000

Share_Based_Awards_Schedule_of

Share Based Awards - Schedule of Option Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
NUMBER OF SHARES, Granted	1,022,500
NUMBER OF SHARES, Ending Balance	1,022,500
NUMBER OF SHARES, Vested and expected to vest	910,184
NUMBER OF SHARES, Exercisable	90,000
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Granted	$9.86
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Ending balance	$9.86
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Vested and expected to vest	$9.87
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Exercisable	$10
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
NUMBER OF SHARES, Beginning Balance	4,835,000
NUMBER OF SHARES, Granted	0
NUMBER OF SHARES, Exercised	-75,000
NUMBER OF SHARES, Forfeited/cancelled	-18,750
NUMBER OF SHARES, Ending Balance	4,741,250
NUMBER OF SHARES, Vested and expected to vest	4,721,276
NUMBER OF SHARES, Exercisable	4,176,250
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Beginning Balance	$0.11
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Exercised	$0.08
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Forfeited/cancelled	$0
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Ending balance	$0.11
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Vested and expected to vest	$0.11
WEIGHTED AVERAGE EXERCISE PRICE PER SHARE, Exercisable	$0.09
AGGREGATE INTRINSIC VALUE, Exercised	$12
AGGREGATE INTRINSIC VALUE, Ending Balance	1,070
AGGREGATE INTRINSIC VALUE, Vested and expected	1,068
AGGREGATE INTRINSIC VALUE, Exercisable	$1,013

Share_Based_Awards_Schedule_of1

Share Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	76.80%
Expected volatility	84.60%
Expected dividends	0.00%
Risk-free rate	1.30%
Risk-free rate	1.80%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years 6 months

Related_Party_Transactions_Sch

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payable to related parties - current
Total	$161	$12
Payable to related parties - noncurrent
Principle amounts due to the Parent		417
Total		417
Management services [Member]
Payable to related parties - current
Management services provided by related parties	$161	$12

Concentration_of_Credit_Risk_A

Concentration of Credit Risk - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Risks and Uncertainties [Abstract]
Cash	$35,263	$138	$207	$584

Operating_Segments_and_Geograp2

Operating Segments and Geographic Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments	1

Operating_Segments_and_Geograp3

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$73	$26
Long Lived Assets	792		747
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	34	22
Korea [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	36
Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		4
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	3
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	762		716
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$30		$31

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	7-May-15	1-May-15
		Installment
		Employees
Subsequent Event [Line Items]
Liquidation plan	In May 2015, the board of directors and shareholders of the Parent approved a plan to voluntarily liquidate the Parent and distribute, in August 2015, to its ordinary shareholders of record as of June 15, 2015, the remaining assets of the company, consisting primarily of 9,666,667 shares of Presbia PLC.
Unvested portions outstanding	910,184
Liquidation date	31-Aug-15
Expiration date of outstanding options	15-Jun-15
Stock options granted	1,022,500
Stock options granted exercise price	$9.86
Presbia Holdings [Member]
Subsequent Event [Line Items]
Unvested portions outstanding	4,721,276
Stock options granted	0
Subsequent Event [Member]
Subsequent Event [Line Items]
Unvested portions outstanding			4,741,250
Restricted shares			1,500,000
Subsequent Event [Member] | Presbia Incentive Plan [Member]
Subsequent Event [Line Items]
Stock options granted		12,500
Number of employees, to whom shares are granted		3
Stock options granted exercise price		$8.82
Vesting annual installments		5
Award expiration period		10 years
Subsequent Event [Member] | Presbia Holdings [Member]
Subsequent Event [Line Items]
Shares outstanding			9,666,667